Roniciclib

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

Product Specifications

CAS Number

[1223498-69-8]

Product Name Alternative

BAY 1000394

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Roniciclib.html

Purity

98.09

Solubility

DMSO : ≥ 250 mg/mL

Smiles

C[C@@H](O)[C@H](OC1=NC(NC2=CC=C([S@@](=N)(C3CC3)=O)C=C2)=NC=C1C(F)(F)F)C

Molecular Formula

C18H21F3N4O3S

Molecular Weight

430.44

References & Citations

[1]Siemeister G, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther. 2012 Oct;11 (10) :2265-73.|[2]Lücking U, et al. The lab oddity prevails: discovery of pan-CDK inhibitor (R) -S-cyclopropyl-S- (4-{[4-{[ (1R,2R) -2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl) pyrimidin-2-yl]amino}phenyl) sulfoximide (BAY 1000394) for the treatment of cancer. ChemMedChem. 2013 Jul;8 (7) :1067-85.